Brentuximab Vedotin, Clinical Trials, CD30-Positive CTCL

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

This study is ongoing, but not recruiting patients.

This is a Randomized, Open-Label, Phase 3 trial of brentuximab vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Study Type:  Interventional

Study Design:        

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Condition:  

Primary Cutaneous Anaplastic Large Cell Lymphoma,
Mycosis Fungoides
Cutaneous T-Cell Lymphoma                                                

Intervention:  

Drug: Brentuximab Vedotin
Drug: Methotrexate or Bexarotene                                            

Phase: Phase 3

External Link:  https://clinicaltrials.gov/show/NCT01578499